Core Insights - On September 23, 2025, Alibaba-W (09988), SMIC (00981), and Shandong Hi-Speed (00412) were the top three companies by trading volume in the Southbound Stock Connect, with trading amounts of 76.09 billion, 58.35 billion, and 55.48 billion respectively [1] - Alibaba-W (09988), SMIC (00981), and Shandong Hi-Speed (00412) also led the trading volume in the Southbound Stock Connect for the Shenzhen-Hong Kong Stock Connect, with trading amounts of 46.11 billion, 35.19 billion, and 19.51 billion respectively [1] Southbound Stock Connect Trading Activity - The top three active companies in the Southbound Stock Connect (Shanghai-Hong Kong) were: - Alibaba-W (09988): 76.09 billion with a net buy of 7.12 billion - SMIC (00981): 58.35 billion with a net buy of 5.73 billion - Shandong Hi-Speed (00412): 55.48 billion with a net sell of 47.24 million [2] - The top three active companies in the Southbound Stock Connect (Shenzhen-Hong Kong) were: - Alibaba-W (09988): 46.11 billion with a net buy of 9.61 billion - SMIC (00981): 35.19 billion with a net sell of 70.31 million - Shandong Hi-Speed (00412): 19.51 billion with a net buy of 17.09 million [2]

Core Viewpoint - The Hong Kong stock market experienced significant net selling from northbound capital, totaling 40.69 billion HKD on September 23, with notable net selling in both Shanghai and Shenzhen stock connects [1] Group 1: Northbound Capital Activity - Northbound capital had a net selling of 40.69 billion HKD, with 23.22 billion HKD from Shanghai Stock Connect and 17.47 billion HKD from Shenzhen Stock Connect [1] - The most bought stocks by northbound capital included Alibaba-W (09988), SMIC (00981), and Kangfang Biotech (09926) [1] - The most sold stocks included the Tracker Fund of Hong Kong (02800), Hang Seng China Enterprises (02828), and Huahong Semiconductor (01347) [1] Group 2: Individual Stock Performance - Alibaba-W saw a net inflow of 7.12 billion HKD, with a total transaction volume of 76.09 billion HKD, driven by promotional activities and support for merchants [2][4] - SMIC recorded a net inflow of 5.73 billion HKD, while Huahong Semiconductor faced a net outflow of 2.33 billion HKD [5] - Kangfang Biotech received a net inflow of 2.19 billion HKD, supported by its participation in a significant clinical study [5] Group 3: ETF and Sector Trends - The Tracker Fund of Hong Kong (02800) and Hang Seng China Enterprises (02828) faced net outflows of 32.71 billion HKD and 9.93 billion HKD, respectively [7] - The technology sector in Hong Kong has seen a rebound, with indices rising nearly 20% since July, indicating potential for further improvement in market sentiment [7]

Group 1: Market Performance - The Hong Kong Innovation Drug ETF (159570) experienced a decline of 1.48% with a trading volume of nearly 2 billion CNY on September 23, 2025, and has seen a net inflow of over 15 billion CNY in the past 10 days [1] - As of September 22, 2025, the total size of the Hong Kong Innovation Drug ETF (159570) exceeded 21.6 billion CNY, leading its peers in both size and liquidity [1] - The underlying index components of the ETF mostly showed negative performance, with notable declines in China Biologic Products and CSPC Pharmaceutical Group, while Kangfang Biotech rose over 4% due to positive research news [1] Group 2: Industry Trends - Morgan Stanley noted that the total market capitalization of Chinese biotech stocks listed in Hong Kong has increased by 154% year-to-date, significantly outperforming the Hang Seng Index's 34% increase, indicating a major shift in market recognition of local pharmaceutical innovation capabilities [2] - The pharmaceutical sector is entering a new development phase driven by innovation, with major companies showing stable growth and transitioning from generic to innovative drugs [3][4] - The pharmaceutical industry is expected to benefit from ongoing policy support for innovative drugs, with recent announcements from the National Medical Insurance Bureau indicating a focus on optimizing drug procurement and supporting innovative products [5] Group 3: Company Performance - Hengrui Medicine reported a revenue of 15.76 billion CNY for H1 2025, a year-on-year increase of 15.88%, with a net profit of 4.45 billion CNY, up 29.67% [4] - China Biologic Products achieved a revenue of 17.58 billion CNY in H1 2025, reflecting a year-on-year growth of 9.8%, with a net profit increase of 13.10% [4] - Innovent Biologics demonstrated significant growth in innovative drug revenue, with a 26% increase in H1 2025, contributing to a 32% rise in net profit [4] Group 4: Future Outlook - The pharmaceutical sector is expected to continue benefiting from improved global liquidity and supportive national policies for innovation, with a focus on emerging technologies and international competitiveness [7] - The industry is anticipated to see long-term growth opportunities, particularly in innovative drugs and medical devices, as well as potential challenges associated with international expansion [7] - The recent adjustments in the national drug procurement policy are expected to stabilize the market for generic drugs, reducing the impact of price competition on the sector [5]

Core Viewpoint - The Hong Kong stock market has experienced significant volatility over the past year, with the Hang Seng Index rising from around 17,000 points to over 27,000 points, marking a new high since 2022, driven by strong performance in sectors like AI, innovative pharmaceuticals, and new consumption [1][2][12] Market Performance - The Hang Seng Index reached a peak of 27,000 points in September 2024, following a series of financial policy announcements and a surprise rate cut by the Federal Reserve [2] - The Hang Seng Technology Index also showed strong performance, climbing from approximately 3,500 points to 6,461 points during the same period [2] - Recent market trends indicate a slight pullback, with the Hang Seng Index closing at 26,159 points, down 0.7%, and the Hang Seng Technology Index at 6,167 points, down 1.45% [1] Sector Analysis - The market has seen a structural shift with active rotation among sectors, including AI, new consumption, and innovative pharmaceuticals, leading to significant stock price increases for major players like Semiconductor Manufacturing International Corporation and Alibaba [7][10] - The innovative pharmaceutical sector has also gained traction, with companies like Innovent Biologics and BeiGene entering substantial partnerships, contributing to a rise in the Hang Seng Innovative Pharmaceutical Index by over 100% [7] Investment Trends - Over the past year, 543 stocks have doubled in price, with notable performers in consumer discretionary, healthcare, and financial sectors, including companies like Genscript Biotech and Zai Lab [9] - The Hong Kong IPO market remains robust, with 51 IPOs raising HKD 128 billion in the first seven months of the year, surpassing the total for the previous year [10] Liquidity and Capital Flow - The liquidity situation in the Hong Kong market has improved significantly, with average daily trading volume increasing by 118% year-on-year to HKD 2,402 billion [2][11] - Southbound capital inflow has been driven by domestic investors seeking stable returns and growth opportunities in Hong Kong, particularly in dividend-paying and growth sectors [11] Future Outlook - Analysts remain optimistic about the future of the Hong Kong stock market, anticipating continued valuation recovery in sectors like technology and new consumption, despite potential short-term lag due to A-share market dynamics [12][13] - The current market cycle is viewed as being in its mid-stage, with liquidity and valuation cycles leading the way, while the earnings cycle is just beginning [12]

Market Overview - The Hong Kong stock market indices collectively declined, with the Hang Seng Technology Index dropping as much as 2.6% before closing down 1.45% [1] - The Hang Seng Index fell 0.7% to remain above 26,000 points, while the National Enterprises Index decreased by 0.86% [1] Sector Performance - Major technology stocks experienced widespread declines, with Baidu falling over 5%, JD.com down 4.4%, Meituan down nearly 3%, Xiaomi down over 1%, and Tencent down nearly 1% [1] - Alibaba managed to close slightly positive, while Apple-related stocks saw significant pullbacks, with Lens Technology down over 7% and both Wasion Group and QiuTai Technology down over 3% [1] - Other sectors such as real estate, automotive, Chinese brokerage firms, steel, lithium battery, gambling, shipping, aviation, and semiconductor stocks also showed weak performance [1] Education Sector - The Ministry of Education announced the establishment of the world's largest vocational education system, leading to a rise in vocational education stocks, with Thinker Education up over 6% and New Oriental, a leader in online education, rising nearly 2% [1] Gold Market - Spot gold reached a new historical high, resulting in active performance among gold stocks [1] Individual Stock Movements - Newly listed stocks saw significant gains, with Yunzhihui Technology soaring over 103% and other companies like Mixue Group and Kangfang Biotech rising 4.7% and 4.28% respectively [1] - Conversely, Guotai Junan International fell by 11.57% and Canggang Railway dropped by 12.5% [1] - Notable gains included Shanga Holdings up 22.25% and Hong Kong Broadband up 15.85% [1]

Industry Rating - The report maintains an "Outperform" rating for the pharmaceutical and biotechnology industry [1]. Core Insights - The Chinese innovative drug industry has established a trend towards global commercialization, supported by a pyramid structure of leading and quality enterprises, indicating strong sustainability in industry development [2]. - The underlying logic of the current cycle is that Chinese innovative drugs possess global competitiveness, shifting from domestic sales to international licensing and commercialization, thus opening up commercial space and maturing the ecosystem [2]. - The focus on differentiated mechanisms or high clinical value "good molecules" remains a core interest for international buyers, with early data being crucial for entering licensing windows [2]. Current Situation - The Chinese innovative drug industry is entering a phase of realization, driven by support from capital markets, policies, and talent [3]. - The industry has developed self-sustaining capabilities through business development (BD) licensing and drug commercialization [3]. - Comprehensive policy support for "true innovation" has been established, enhancing the industry's growth [3]. Future Outlook - Continued collaboration among academia, industry, and research will enhance the output of first-in-class (FIC) molecules, with China becoming one of the most efficient countries in the drug development pathway [4]. - Higher innovation levels are expected to further unlock commercial value, indicating a promising future for the industry [4]. Investment Recommendations - Focus on global blockbuster products: companies such as BeiGene, Kelun-Biotech, Innovent Biologics, and others are highlighted as key players [5]. - Attention to global best-in-class (BIC) potential companies, including EdiGene, Zai Lab, and others, is recommended [5]. - Domestic blockbuster products and asset values of companies like Hengrui Medicine and others are also suggested for consideration [5].

每经AI快讯，9月23日，港股康方生物(09926.HK)涨近5%，截至发稿，涨4.96%，报137.5港元，成交额 12.12亿港元。 ...

Core Viewpoint - Kangfang Biotech (09926) shares rose nearly 5%, currently up 4.96% at HKD 137.5, with a trading volume of HKD 1.212 billion, driven by the upcoming presentation of its innovative bispecific antibody drug, Ivosidenib, at the ESMO 2025 conference [1] Company Summary - Kangfang Biotech's Ivosidenib (PD-1/VEGF bispecific antibody) is set to be featured in a Late-Breaking Abstract at the ESMO 2025 conference, with a significant presentation by Professor Lu Shun, the principal investigator of the Phase III clinical study comparing it to Tislelizumab for treating advanced squamous non-small cell lung cancer (sq-NSCLC) [1] - The company is recognized for its innovative capabilities, which have contributed to a substantial increase in its stock value [1] Industry Summary - Morgan Stanley reported that the total market capitalization of Chinese biotech stocks listed in Hong Kong has increased by 154% year-to-date, significantly outperforming the Hang Seng Index's 34% rise, indicating a major shift in market recognition of local pharmaceutical innovation [1] - The expectation of accelerated interest rate cuts by the Federal Reserve is anticipated to enhance risk appetite, directing funds towards growth sectors like Chinese biotech [1] - Despite the positive outlook, Morgan Stanley cautioned that individual stock performance will still depend on company fundamentals, including commercialization execution and innovation progress, highlighting companies with short-term catalysts, such as Kangfang Biotech [1]

Group 1 - The core viewpoint of the article highlights the significant rise in the stock price of Kangfang Biotech (09926), which increased by nearly 5% to HKD 137.5, with a trading volume of HKD 1.212 billion [1] - Kangfang Biotech's innovative bispecific antibody drug, Ivosidenib (PD-1/VEGF bispecific), has been selected for a Late-Breaking Abstract presentation at the 2025 European Society for Medical Oncology (ESMO) annual meeting, scheduled for October 17-21 in Berlin [1] - The primary investigator, Professor Lu Shun from Shanghai Chest Hospital, will present the results of the pivotal Phase III clinical study (AK112-306/HARMONi-6) comparing Ivosidenib combined with chemotherapy against Tislelizumab combined with chemotherapy for first-line treatment of advanced squamous non-small cell lung cancer (sq-NSCLC) at the Presidential Symposium [1] Group 2 - Morgan Stanley's report indicates that the total market capitalization of Chinese biotech stocks listed in Hong Kong has increased by 154% year-to-date, significantly outpacing the Hang Seng Index's 34% rise, reflecting a major shift in market recognition of local pharmaceutical companies' innovation capabilities [1] - The report anticipates that the Federal Reserve's accelerated interest rate cuts will enhance risk appetite, directing funds towards growth sectors such as Chinese biotech [1] - However, Morgan Stanley notes that the performance of individual stocks will still depend on the companies' fundamentals, including commercialization execution and innovation research progress, expressing optimism for companies with short-term catalysts like Kangfang Biotech [1]

Group 1 - The core point of the article highlights that the total market capitalization of Chinese biotech stocks listed in Hong Kong has increased by 154% year-to-date, significantly outperforming the Hang Seng Index's 34% rise, indicating a major shift in market recognition of local pharmaceutical companies' innovation capabilities [1] - The report anticipates that the Federal Reserve's accelerated interest rate cuts will enhance risk appetite, directing funds towards growth sectors such as Chinese biotechnology [1] - However, the performance of individual stocks is expected to depend on company fundamentals, including commercialization execution and innovation research progress [1] Group 2 - The report expresses optimism for companies with short-term catalysts, specifically naming Kangfang Biotech (09926), Nuo Cheng Jian Hua (09969), and others as potential beneficiaries [1] - Additionally, it assigns an "outperform" rating to Weisheng Pharmaceutical-B (02561) and Zai Lab (09688) [1]